BSWRI’s most recent COVID-19 research endeavor was featured in an exclusive story published by the Dallas Morning News as well as a number of other local and national outlets. The trial examines a new monoclonal antibody, produced by Eli Lilly and AbCellera Biologics, which has been shown to neutralize all known variants of concern in early lab tests.